Psychotropic burden → Function
The RESTORE Project
From symptom stabilization to functional recovery.
RESTORE examines whether post-release psychotropic and sedative burden is associated with impaired functioning—and whether the perceived temporary restoration of energy, alertness, motivation, concentration, or emotional responsiveness may be an underrecognized factor in methamphetamine use or relapse.
In progressHypothesis-generatingNo causal claims
RESTORE began with recurring clinical observations. Those observations do not establish prevalence, mechanism, or causation. The framework converts them into measurable questions while preserving appropriate psychiatric treatment and testing alternative explanations.
The four RESTORE questions
A proposed pathway to investigate, not a pathway already proven.
Functional impairment → Methamphetamine use
For some individuals, is methamphetamine use partly an attempt to restore perceived functioning?
Treatment optimization → Functional recovery
Can systematic reassessment and individualized treatment optimization improve real-world functioning?
Functional recovery → Methamphetamine relapse
If functioning improves, is methamphetamine relapse or continued use reduced?
Clinical observation and research gap
What if “trying to function” is part of the story?
In post-incarceration care, some patients describe methamphetamine as temporarily restoring energy, focus, motivation, or emotional responsiveness—not only as producing euphoria. This does not minimize addiction, craving, withdrawal, psychiatric illness, trauma, or the social conditions that influence substance use.
RESTORE asks whether perceived functional restoration is an additional, underrecognized factor for some individuals and whether it can be studied without assuming that medication burden caused the methamphetamine use.
Methods and evaluation
A proposed prospective, mixed-methods feasibility evaluation.
The initial aim is feasibility and signal detection—not proof of causation. No participant outcome data are reported at this stage.
- 1Reconcile treatment
Document diagnoses, medications, doses, timing, indications, and cumulative sedative or anticholinergic burden.
- 2Measure repeatedly
Assess sleepiness, anhedonia/amotivation, cognition, psychiatric symptoms, daily functioning, craving/use, and reentry conditions.
- 3Listen systematically
Use structured interviews to characterize patient-reported motives for and perceived effects of methamphetamine.
- 4Observe clinically indicated change
Evaluate within-person changes after individualized treatment optimization, while accounting for competing explanations.
Progress to date
The clinical observation has been translated into a four-question logic model, candidate measurement domains, and a proposed longitudinal evaluation. Protocol and measure selection remain in development.
Diversity, equity, and inclusion
Functional recovery must be studied in the realities of reentry.
People returning from incarceration experience disproportionate psychiatric, substance-use, housing, employment, and care-access barriers. These conditions may influence both functioning and relapse and must not be treated as background noise.
Include patient-reported functioning and the outcomes that matter to daily life.
Monitor patterns across race and ethnicity, gender, disability, housing status, and other social conditions.
Use person-first language and do not interpret functional difficulty as moral failure or lack of motivation.
Medication review must never remove necessary treatment solely for research purposes.
Clinical practice take-home messages
After release, reassess diagnosis, medication burden, sedation, cognition, and daily function while maintaining necessary treatment.
Ask what methamphetamine is perceived to do for the patient; the answer may reveal functional treatment targets without minimizing addiction risk.
Scientific references
Evidence informing the framework
- Reeve S, Robbins K, Hodgekins J. The psychological consequences of the sedating side effects of antipsychotic medication: a systematic review. Psychiatry Research. 2025;351:116641. doi:10.1016/j.psychres.2025.116641.
- Huhn M, et al. Antipsychotic drugs and cognitive function: a systematic review and network meta-analysis. JAMA Psychiatry. 2024;81(10):1006–1018. doi:10.1001/jamapsychiatry.2024.2063.
- Sekhon S, et al. Continuity of mental health care during the transition from prison to the community following brief periods of imprisonment. BMC Health Services Research. 2022;22:1300. doi:10.1186/s12913-022-08656-7.
- Hart CL, et al. Methamphetamine self-administration by humans. Psychopharmacology. 2001;157:75–81. doi:10.1007/s002130100738.
RESTORE project materials
Download the scientific companion and CSAM 2026 poster.
The 46-page scientific companion provides the detailed evidence map, four fictionalized composite cases, clinical guardrails, and proposed evaluation blueprint. The poster presents the concise scientific framework.